Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (245)	4/6/2005 11:22:10 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 566

Online download costs $30. Efficacy and Safety Clinical Data for Rigel's R112 Phase II Study Published in Journal of Allergy and Clinical Immunology Wednesday April 6, 7:00 am ET - Rigel's R112 Compound, an Inhibitor of Syk Kinase, Shows Promise for the Treatment of Allergic Rhinitis SOUTH SAN FRANCISCO, Calif., April 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that the Journal of Allergy and Clinical Immunology has published the Phase II clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis. The article titled, "An Intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment," is included in the April 2005 issue of the Journal. The article reviews the clinical Phase II data results for R112, concluding that patients in a park-like setting demonstrated a significant improvement in their allergic rhinitis symptoms when treated with R112, and confirmed that the drug candidate was well tolerated and had a favorable safety profile. The article and abstract can be viewed and downloaded at aaaai.org . <snip>